Sarcopenia predicts adverse outcomes in an elderly population with coronary artery disease: a systematic review and meta-analysis

Table 1 Adverse outcomes for sarcopenia versus non-sarcopenia

	N	HR (95%CI)	P	I², %	P_{(Heterogeneity)}
MACE overall	7	2.273 (1.581–3.268)	< 0.001	60	0.02
Other	2	2.769 (1.630–4.706)	< 0.001	67.5	0.079
PMI	3	2.861 (1.835–4.460)	< 0.001	0	0.604
SMI/height squared	2	1.319 (0.570–3.050)	0.518	68.2	0.076
Prospective cohort	4	2.232 (1.278–3.898)	0.005	78.8	0.003
Retrospective cohort	3	2.315 (1.460–3.670)	< 0.001	0	0.665
CAD	3	1.979 (0.984–3.983)	0.056	84.2	0.002
Non-STEMI	1	3.320 (1.727–6.381)	< 0.001
CABG	1	1.960 (0.827–4.644)	0.126
Heart valve surgery	1	3.210 (1.374–7.501)	0.007
STEMI	1	2.060 (1.011–4.196)	0.046
Late mortality	3	2.152 (0.887–5.223)	0.09	91	< 0.001
Heart valve surgery	2	1.548 (0.7–3.422)	0.281	85.2	0.009
CABG	1	4.250 (2.181–8.283)	< 0.001
Death, HF-related hospitalization	2	1.370 (0.594–3.164)	0.459	62	0.105
All-cause mortality	2	1.354 (0.143–12.842)	0.792	90.5	0.001

HR hazard ratio, CI confidence interval, MACE major adverse cardiovascular event, PMI psoas muscle area index, SMI skeletal muscle area index, CAD coronary artery disease, STEMI ST-elevated myocardial infarction, CABG coronary artery bypass graft, HF heart failure

ISSN: 1471-2318